Johnson & Johnson Acquires Neuropharmaceutical Company for $14.6 Billion

On January 13, Johnson & Johnson announced that it has reached a final agreement with biopharmaceutical company Intra-Cellular Therapies, which focuses on the development and commercialization of drugs for central nervous system (CNS) diseases. Under the agreement, Johnson & Johnson will acquire all outstanding shares of Intra-Cellular Therapies at a price of $132 per share, totaling approximately $14.6 billion.

The core asset of Intra-Cellular Therapies includes the orally administered antipsychotic product Caplyta (lumateperone). This drug is a 5-HT2A receptor antagonist and D2 dopamine receptor modulator, originally developed by Bristol-Myers Squibb (BMS) and licensed to Intra-Cellular Therapies for global development in 2015. In December 2019, Caplyta was approved by the FDA for the treatment of schizophrenia in adults. In December 2021, the drug was also approved for the adjunctive treatment of depressive episodes associated with bipolar I or II disorder. Furthermore, Intra-Cellular Therapies submitted a new indication application for Caplyta to the FDA in December 2024 for the adjunctive treatment of major depressive disorder (MDD) and is exploring its use in pediatric indications and long-acting formulations.

Through this acquisition, Johnson & Johnson will also gain access to several pipeline candidates, including ITI-1284, lenrispodun, ITI-1020, ITI-333, and ITI-1549, further strengthening its pipeline in neuroscience. With the surge in mental health crises and the aging global population, over 1 billion people worldwide (or 1 in every 8 individuals) suffer from neuropsychiatric or neurodegenerative diseases. This substantial patient market has attracted numerous pharmaceutical companies.

For instance, in December 2023, Bristol-Myers Squibb acquired Karuna Therapeutics for $14 billion, gaining the potential new schizophrenia drug Cobenfy (formerly KarXT), which was approved by the FDA in 2024. In the same month, AbbVie purchased Cerevel for $8.7 billion, obtaining several promising candidates for diseases such as schizophrenia, Parkinson's disease, and mood disorders. However, AbbVie's flagship project emraclidine failed to meet its expected endpoints in two Phase II studies targeting schizophrenia, reflecting the high-risk nature of new drug development in the neuroscience field. In October 2024, AbbVie acquired Aliada for $1.4 billion, securing its main project for Alzheimer's disease treatment ALIA-1758 to bolster its neuroscience pipeline. Similarly, in October 2024, Langbo Pharmaceuticals acquired Longboard Pharmaceuticals for $2.6 billion, obtaining a new epilepsy drug Bexicaserin.

Johnson & Johnson's $14.6 billion acquisition of Intra-Cellular Therapies will undoubtedly inject new vitality into the neuroscience field. In 2024, there was only one merger in the pharmaceutical industry exceeding $10 billion, but at the start of 2025, Johnson & Johnson has made the first significant acquisition. With the JPM conference underway, more merger transactions are expected to occur in the pharmaceutical industry in the coming days.